within Pharmacolibrary.Drugs.ATC.V;

model V08CA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0018333333333333333,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Gadoversetamide is a gadolinium-based contrast agent previously used for magnetic resonance imaging (MRI) to enhance visualization of blood vessels and tissues. It was utilized particularly for central nervous system and whole body MRI, but has been discontinued in several markets due to concerns about nephrogenic systemic fibrosis (NSF) in patients with impaired renal function.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated in healthy adult subjects after intravenous bolus administration.</p><h4>References</h4><ol><li><p>Wible, JH, et al., &amp; Kearns, GL (2009). Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients. <i>Magnetic resonance imaging</i> 27(4) 512–518. DOI:<a href=&quot;https://doi.org/10.1016/j.mri.2008.08.002&quot;>10.1016/j.mri.2008.08.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18814985/&quot;>https://pubmed.ncbi.nlm.nih.gov/18814985</a></p></li><li><p>Baker, JF, et al., &amp; Wible, JH (2004). Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects. <i>Investigative radiology</i> 39(6) 334–339. DOI:<a href=&quot;https://doi.org/10.1097/01.rli.0000124455.11402.52&quot;>10.1097/01.rli.0000124455.11402.52</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15167099/&quot;>https://pubmed.ncbi.nlm.nih.gov/15167099</a></p></li><li><p>Swan, SK, et al., &amp; Pierro, JA (1999). Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. <i>Journal of magnetic resonance imaging : JMRI</i> 9(2) 317–321. DOI:<a href=&quot;https://doi.org/10.1002/(sici)1522-2586(199902)9:2&lt;317::aid-jmri25&gt;3.0.co;2-b&quot;>10.1002/(sici)1522-2586(199902)9:2&lt;317::aid-jmri25&gt;3.0.co;2-b</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10077031/&quot;>https://pubmed.ncbi.nlm.nih.gov/10077031</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V08CA06;
